Randomised, Double-Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Graded Doses of STX-100/Alhydrogel, a Recombinant Enterovirus A 71 (EV-A71) Virus-Like Particle Vaccine in Healthy Adults

Trial Profile

Randomised, Double-Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Graded Doses of STX-100/Alhydrogel, a Recombinant Enterovirus A 71 (EV-A71) Virus-Like Particle Vaccine in Healthy Adults

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs STX 100/Alhydrogel (Primary)
  • Indications Enterovirus A infections
  • Focus Adverse reactions; First in man
  • Sponsors Sentinext Therapeutics
  • Most Recent Events

    • 15 Jan 2018 Planned End Date changed from 5 Feb 2018 to 2 Aug 2018.
    • 15 Jan 2018 Planned initiation date changed from 18 Jul 2017 to 18 Jan 2018.
    • 15 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top